BioCentury | Oct 27, 2014
Clinical News

Rixubis regulatory update

...EMA's CHMP recommended approval of Rixubis from Baxter for treatment and prophylaxis of bleeding in patients...
...children and adults with hemophilia B. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Rixubis ( BAX 326...
BioCentury | Oct 25, 2014
Company News

Baxter's Rixubis gets CHMP nod for hemophilia B

...EMA's CHMP recommended marketing authorization of Rixubis ( BAX 326 ) from Baxter International Inc. (NYSE:BAX) to...
...year for use in adults with hemophilia B. Last month, FDA approved an sBLA for Rixubis...
BioCentury | Sep 22, 2014
Clinical News

Rixubis regulatory update

...FDA approved an sBLA from Baxter for Rixubis to control and prevent bleeding episodes, for perioperative...
...use in adults with hemophilia B. Last October, Baxter submitted an MAA to EMA for Rixubis...
...of bleeding in hemophilia B patients. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Rixubis ( BAX 326...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...A/S (CSE:BAVA) Imvanex vaccine Immunization against smallpox disease in adults Canada/EU Baxter International Inc. (NYSE:BAX) Rixubis...
BioCentury | Dec 16, 2013
Clinical News

Rixubis: Phase II/III data

...patients aged <12 years with severe or moderately severe hemophilia B showed that twice-weekly prophylactic Rixubis...
...annualized bleeding rate of 2.0, with 9 patients experiencing no bleeds. Additionally, hemostatic efficacy of Rixubis...
...BioCentury, July 1 & Nov. 4). Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Rixubis ( BAX 326...
BioCentury | Nov 4, 2013
Clinical News

Rixubis regulatory update

...Baxter submitted an MAA to EMA for Rixubis for the treatment and prophylaxis of bleeding in...
...>=16 years (see BioCentury, July 1). Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Rixubis ( BAX 326...
BioCentury | Nov 1, 2013
Company News

Baxter submits MAA for hemophilia B product

...Baxter International Inc. (NYSE:BAX) submitted an MAA to EMA for Rixubis ( BAX 326 ) for the...
BioCentury | Jul 1, 2013
Clinical News

Rixubis regulatory update

...FDA approved a BLA for Rixubis from Baxter to treat hemophilia B in patients >=16 years...
...perioperative management and for routine prophylactic use to prevent or reduce bleeding episodes. FDA said Rixubis...
...in the EU before year end. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Rixubis ( BAX 326...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...IV Gammagard and recombinant human PH20 hyaluronidase enzyme (rHuPH20) Baxter International Inc. (NYSE:BAX) FDA approves Rixubis...
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Punctuated equilibrium

...renal impairment and rare fungal infections Ph III VITAL data 2H13 Baxter International Inc. (NYSE:BAX) Rixubis...
Items per page:
1 - 10 of 17